1. Home
  2. CYCC vs LQR Comparison

CYCC vs LQR Comparison

Compare CYCC & LQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • LQR
  • Stock Information
  • Founded
  • CYCC 1992
  • LQR 2021
  • Country
  • CYCC United States
  • LQR United States
  • Employees
  • CYCC N/A
  • LQR N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • LQR
  • Sector
  • CYCC Health Care
  • LQR
  • Exchange
  • CYCC Nasdaq
  • LQR Nasdaq
  • Market Cap
  • CYCC 2.3M
  • LQR 2.6M
  • IPO Year
  • CYCC N/A
  • LQR 2023
  • Fundamental
  • Price
  • CYCC $0.34
  • LQR $1.15
  • Analyst Decision
  • CYCC Buy
  • LQR Strong Buy
  • Analyst Count
  • CYCC 2
  • LQR 3
  • Target Price
  • CYCC $11.00
  • LQR $4.89
  • AVG Volume (30 Days)
  • CYCC 431.0K
  • LQR 300.7K
  • Earning Date
  • CYCC 11-12-2024
  • LQR 11-14-2024
  • Dividend Yield
  • CYCC N/A
  • LQR N/A
  • EPS Growth
  • CYCC N/A
  • LQR N/A
  • EPS
  • CYCC N/A
  • LQR N/A
  • Revenue
  • CYCC $74,000.00
  • LQR $2,272,001.00
  • Revenue This Year
  • CYCC N/A
  • LQR $390.35
  • Revenue Next Year
  • CYCC $88.68
  • LQR $102.18
  • P/E Ratio
  • CYCC N/A
  • LQR N/A
  • Revenue Growth
  • CYCC N/A
  • LQR 158.05
  • 52 Week Low
  • CYCC $0.32
  • LQR $0.40
  • 52 Week High
  • CYCC $4.00
  • LQR $3.47
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 37.88
  • LQR 73.55
  • Support Level
  • CYCC $0.33
  • LQR $1.10
  • Resistance Level
  • CYCC $0.42
  • LQR $1.21
  • Average True Range (ATR)
  • CYCC 0.04
  • LQR 0.12
  • MACD
  • CYCC 0.01
  • LQR 0.01
  • Stochastic Oscillator
  • CYCC 8.21
  • LQR 89.04

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

About LQR LQR House Inc.

LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition thereof, and drive sales thereof through its e-commerce platform partner.

Share on Social Networks: